Images List Premium Download Classic

Elan

Elan-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
NEW Peripheral wiring structure of display substrate, display substrate display paneland display device
Boe Technology Group Co., Ltd.
June 22, 2017 - N°20170176789

An embodiment of the present disclosure relates to the field of display technology, especially to a peripheral wiring structure of a display substrate, and a display substrate. In each two adjacent wirings on a display substrate, a first peripheral wiring structure has a first bent part which includes a first inclined surface, a first top surface, a second inclined surface; ...
NEW Method of diagnosing and monitoring bladder cancer and melanoma
Boe Technology Group Co., Ltd.
June 22, 2017 - N°20170176437

The present invention provides a method for the diagnosing and monitoring of melanoma
NEW Composition and method of using mir-302 precursors as anti-cancer drugs for treating human lung cancer
Boe Technology Group Co., Ltd.
June 22, 2017 - N°20170175118

This invention generally relates to a composition and method of using mam-made small rnas, such as small interfering rnas (sirna), micrornas (mirna) and their hairpin-like precursors (pre-mirna), as tumor suppressing anti-cancer drugs for treating human tumors and cancers, in particular, but not limited, for treating skin (melanoma), blood (leukemia), prostate, breast, liver and lung cancers as well as various neoplastic ...
NEW Elan Patent Pack
Download + patent application PDFs
Elan Patent Applications
Download + Elan-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Elan-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
NEW Systems and methods for production of artificial eumelanin
The Board Of Regents For Oklahoma State University
June 22, 2017 - N°20170174825

“black” photoactive materials that comprise synthetic eumelanin polymers are provided, as are methods of making and using the polymers. The synthetic eumelanin polymers are made from the plant oil vanillin, and exhibit defined structural and chemical characteristics (e. G. Homogeneity, solubility, etc.) that make them suitable for use in devices that require photoactive materials, such as ...
NEW Use of anti-pd-1 antibody in combination with anti-cd27 antibody in cancer treatment
Celldex Therapeutics, Inc
June 22, 2017 - N°20170174774

This invention provides methods for treating cancer in a subject comprising administering to the subject an anti-pd-1 antibody and an anti-cd27 antibody. In some embodiments, the cancer is colorectal cancer, rectal cancer, colon cancer, lung cancer, melanoma, ovarian cancer, head and neck cancer, or any combination thereof.
NEW New method for treating melanoma
UniversitÉ Pauls Sabatier Toulouse Iii
June 22, 2017 - N°20170174744

The present invention relates to a tnfα blocking agent for use in the treatment and prevention of melanoma in a subject in whom melanoma cells express mhci and in whom stroma cells exhibit tnf expression.
NEW Elan Patent Pack
Download + patent application PDFs
Elan Patent Applications
Download + Elan-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Elan-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
NEW Pyrazolone compounds and uses thereof
Inception 2, Inc.
June 22, 2017 - N°20170174666

The invention disclosed herein is directed to compounds of formula i [formula should be entered here] and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, acute or chronic myeloid leukemia, melanoma, and other cancers. The invention also includes pharmaceutical compositions comprising a therapeutically effective amount of compound of formula ...
NEW Histone demethylase inhibitors
Celgene Quanticel Research, Inc.
June 22, 2017 - N°20170174656

The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted 3-aminopyridine derivative compounds, substituted 3-aminopyridazine derivative compounds, and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, ...
NEW Exogenous tap inhibitor armed oncolytic viruses and therapeutic uses thereof
Benevir Biopharm, Inc.
June 22, 2017 - N°20170173092

The present invention relates to exogenous tap inhibitor armed oncolytic viruses that replicate selectively in cancer cells, evade cd8+ cytolytic t-cells, and induce the immune system to recognize tumor cells. Preferred viruses of the invention have a heterologous gene that encodes a function that affects antigen presentation by inhibiting tap. The viruses of the invention also comprise one or more ...
NEW Methods of treating melanoma
Mitchell Woods Pharmaceuticals, Inc.
June 22, 2017 - N°20170172944

Methods of regulating disorders and diseases in cells expressing β2-adrenergic receptor (ar), cannabinoid (cb) receptor and epidermal growth factor receptor (egfr), include treating a disorder or disease, such as a melanoma include administration of a fenoterol analogue.
NEW Tyrosine derivatives and compositions comprising them
Tyme, Inc.
June 22, 2017 - N°20170172924

Provided herein are methods comprising providing a tyrosine derivative and a solid particulate material (and, optionally, melanin) and applying force to said tyrosine derivative and said solid particulate material for a time and under conditions effective to impregnate at least one of said tyrosine derivative and said solid particulate material with the other of said tyrosine derivative and said solid ...
See what's behind you (swby - pronounced "swee-bee")
Tyme, Inc.
June 15, 2017 - N°20170171515

It's used during personal outdoor activities that bring concern and it's used in professional industries such as branches of homeland security to enhance safety with rear vision. It exposes elements of surprise attacks giving people the advantage to conspicuously judge the situation, respond to it quickly and appropriately while lessening their chance of becoming a victim, the real time video ...
6-substituted quinazolinone inhibitors
Southern Research Institute
June 15, 2017 - N°20170166557

The present technology relates to compounds and compositions of formulas and methods using such compounds. The compounds and compositions described herein may be used in the treatment or prophylaxis of diseases associated with an alphavirus, for example, venezuelan equine encephalitis virus (veev).
Elan Patent Pack
Download + patent application PDFs
Elan Patent Applications
Download + Elan-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Elan-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
New strategies for treating melanoma
Institut Jules Bordet
June 15, 2017 - N°20170165240

The present invention relates to a p53-activating agent capable of transferring wild-type tumor protein p53 (p53) from an inactive conformation into an active conformation capable of inducing apoptosis, for use in the treatment of melanoma, wherein said p53-activating agent is administered simultaneously or sequentially with a braf-inhibiting agent capable of inhibiting activity of serine/threonine-protein kinase b-raf (braf) ...
Complexes of sirolimus and its derivatives, process for the preparation thereof and pharmaceutical compositions containing ...
Druggability Technologies Ip Holdco Limited
June 15, 2017 - N°20170165237

The invention is directed to a stable complex with controlled particle size, increased apparent solubility and increased dissolution rate comprising as active compound sirolimus or derivatives thereof, which is useful in the prophylaxis of organ rejection in patients receiving renal transplants, in the treatment of psoriasis, facial angiofibromas associated with tuberous sclerosis, fibrofolliculomas found in birt-hogg-dubé syndrome, chronic erosive ...
Histone demethylase inhibitors
Celgene Quanticel Research, Inc.
June 08, 2017 - N°20170158685

The present disclosure relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyridine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, ...
Histone demethylase inhibitors
Celgene Quanticel Research, Inc.
June 08, 2017 - N°20170158681

The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted amidopyridine or amidopyridazine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, ...
Histone demethylase inhibitors
Celgene Quanticel Research, Inc.
June 08, 2017 - N°20170158664

Provided herein are substituted pyrazolylpyridine, pyrazolylpyridazine, and pyrazolylpyrimidine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.
Methods of treating zika virus, mers-cov, chikungunya, venezuelan equine encephalitus, and rhinovirus in mammalian patients
Tamir Biotechnology, Inc.
June 08, 2017 - N°20170157219

Viral infections in mammals can be treated and prophylactically prevented by systemic administration of ranpirnase and three other ribonucleases that are highly homologous with it and that have activities that are highly similar to it. Experimental results against zika virus, middle east respiratory syndrome coronavirus (“mers-cov”), chikungunya virus, venezuelan equine encephalitis, and rhinovirus-14 are disclosed.
Mass spectrometry imaging of benign melanocytic nevi and malignant melanomas
Yale University
June 01, 2017 - N°20170154759

A method of differentiating benign melanocytic nevi from malignant melanomas is disclosed. The method generally includes subjecting a skin lesion sample from a patient to mass spectrometry to obtain a mass spectrometry protein profile. This profile is compared to mass spectrometry protein profiles of reference samples, which include known normal, benign melanocytic nevi, and/or malignant melanomas. Classification of the ...
Melanocortin-1 receptor-specific linear peptides
Yale University
May 25, 2017 - N°20170145056

Where z, y, xaa1, xaa2, xaa3, xaa4, xaa5, and xaa6 are as defined in the specification, compositions and formulations including peptides of the foregoing formula or salts thereof, and pharmaceutical compositions for preventing, ameliorating or treating melanocortin-1 receptor-mediated or responsive diseases, indications, conditions and syndromes.
Loading